Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. (Q46162263)

PubMed ID

19145271

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19145271%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

author name string

H Barton Grossman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

Michael A O'Donnell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

Michael S Cookson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

Richard E Greenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

Thomas E Keane

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

publication date

1 January 2008

1 reference

PubMed ID

19145271

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19145271%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

page(s)

281-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

13 May 2020

cites work

1 reference

12 December 2020

Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy?

1 reference

12 December 2020

Impact of body mass index on radical cystectomy.

1 reference

12 December 2020

Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological Stage

1 reference

12 December 2020

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

1 reference

12 December 2020

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

1 reference

12 December 2020

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

1 reference

12 December 2020

Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer

1 reference

12 December 2020

Review of Mayo Clinic experience with carcinoma in situ.

1 reference

12 December 2020

The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?

1 reference

12 December 2020

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer

1 reference

12 December 2020

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

12 December 2020

Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy

1 reference

12 December 2020

Nomograms provide improved accuracy for predicting survival after radical cystectomy.

1 reference

12 December 2020

Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study

1 reference

12 December 2020

Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee

1 reference

12 December 2020

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Photodynamic diagnosis following topical application of delta-aminolevulinic acid in a rat bladder tumor model

1 reference

12 December 2020

Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression

1 reference

12 December 2020

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

12 December 2020

Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study.

1 reference

12 December 2020

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

1 reference

12 December 2020

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

1 reference

12 December 2020

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group

1 reference

12 December 2020

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

1 reference

12 December 2020

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder

1 reference

12 December 2020

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed

1 reference

12 December 2020

A re-staging transurethral resection predicts early progression of superficial bladder cancer

1 reference

12 December 2020

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

1 reference

12 December 2020

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

1 reference

12 December 2020

Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival

1 reference

12 December 2020

Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2615101&resulttype=core&format=json

13 May 2020

1 reference